GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders episode artwork

EPISODE · Dec 3, 2025 · 11 MIN

GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders

from WTR Small-Cap Spotlight · host Water Tower Research

Send us Fan MailOn the latest WTR Small-Cap Spotlight podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and commercializing novel disease-modifying gene therapies aimed at reversing vision loss from severe neurodegenerative retinal diseases. He discusses GenSight's development pipeline, what's unique about  the company's approach to gene therapy and upcoming target milestones.

Episode metadata supplied by the publisher feed · Published Dec 3, 2025

Embed this episode

NOW PLAYING

GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders

0:00 11:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of WTR Small-Cap Spotlight?

This episode is 11 minutes long.

When was this WTR Small-Cap Spotlight episode published?

This episode was published on December 3, 2025.

Can I download this WTR Small-Cap Spotlight episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!